Effective antimalarial pharmacology cannot be understood without a precise grasp of the Plasmodium life cycle, because each drug class acts at a specific parasite stage and the clinical consequence of that stage-specificity determines the drug’s utility for treatment versus prophylaxis, its ability to prevent relapse, and its role in transmission interruption. The four species pathogenic in humans (P. falciparum, P. vivax, P. ovale, and P. malariae) share the same essential two-host cycle but differ in tissue tropism, hepatic dormancy, relapse potential, and susceptibility to available drugs.
The life cycle begins when an infected female Anopheles mosquito injects sporozoites into the human bloodstream during a blood meal. Sporozoites circulate briefly and then enter hepatocytes, initiating the exoerythrocytic (hepatic) stage. Within hepatocytes, sporozoites differentiate into schizonts (hepatic schizonts) that undergo asexual multiplication, producing thousands of merozoites over 5 to 16 days depending on species. Hepatic schizonts then rupture, releasing merozoites into the bloodstream to begin the erythrocytic cycle. A critical complication arises in P. vivax and P. ovale infections: some sporozoites differentiate not into replicating hepatic schizonts but into dormant hypnozoites, which persist in hepatocytes for months to years and serve as the reservoir for delayed relapse. No drug class active against blood-stage parasites eliminates hypnozoites; only the 8-aminoquinolines (primaquine and tafenoquine) reach and kill this hepatic latent stage.1
Once merozoites enter the bloodstream, they invade erythrocytes by binding to specific surface receptors: P. falciparum uses glycophorin A and band 3, while P. vivax requires the Duffy antigen receptor for chemokines (DARC) on the erythrocyte surface, which explains the natural resistance of Duffy-negative individuals (common in West African populations) to P. vivax infection. Within the erythrocyte, merozoites develop through ring, trophozoite, and schizont stages in a cycle of approximately 48 hours for P. falciparum, P. vivax, and P. ovale (tertian fever pattern) and 72 hours for P. malariae (quartan fever pattern). Erythrocytic schizont rupture releases new merozoites and malarial toxins including glycosylphosphatidylinositol (GPI) anchors and hemozoin (malaria pigment), triggering the cyclical fever, rigors, and systemic inflammation that characterize clinical malaria.2
Some erythrocytic parasites differentiate into sexual forms called gametocytes rather than proceeding through asexual schizogony. Gametocytes are taken up by a feeding mosquito, undergo fertilization in the mosquito midgut to form an ookinete, which then develops through oocyst to sporozoite stages before migrating to the salivary glands to complete the transmission cycle. Most blood-stage antimalarials have no gametocytocidal activity against mature P. falciparum gametocytes; primaquine has unique activity against mature P. falciparum gametocytes and is used as a single dose for transmission blocking in WHO elimination strategies.13
Stage-Specific Drug Activity Framework. Understanding which life cycle stage each drug targets is the foundation of rational antimalarial prescribing. Drugs active against hepatic schizonts (causal prophylactics) include atovaquone-proguanil and doxycycline, which kill developing hepatic schizonts before they release merozoites and thus prevent erythrocytic infection entirely. Blood schizonticides (the largest drug class) include chloroquine, quinine, mefloquine, artemisinin derivatives, and atovaquone-proguanil; these eliminate erythrocytic parasites but have no activity against hypnozoites. Antirelapse agents active against hypnozoites are limited to primaquine and tafenoquine (8-aminoquinolines), both of which require glucose-6-phosphate dehydrogenase (G6PD) screening before use due to the risk of hemolytic anemia in G6PD-deficient individuals. Suppressive prophylactics such as chloroquine and mefloquine do not kill hepatic-stage parasites but suppress the erythrocytic cycle, and in P. vivax/P. ovale infections must be combined with primaquine or tafenoquine at treatment completion to prevent relapse from residual hypnozoites.4
Causal prophylaxis (atovaquone-proguanil, doxycycline): kills hepatic schizonts; preferred for travelers to chloroquine-resistant areas. Suppressive prophylaxis (chloroquine, mefloquine): kills blood-stage parasites only; terminal primaquine required for P. vivax/P. ovale to eradicate hypnozoites. Relapse prevention: primaquine 14-day course or tafenoquine single dose after completion of blood-stage treatment; G6PD testing mandatory before either agent. Transmission blocking: single-dose primaquine 0.25 mg/kg in P. falciparum elimination campaigns; no effect on clinical illness.
The quinoline antimalarials are a structurally diverse group united by a quinoline ring core. They include the 4-aminoquinolines (chloroquine, hydroxychloroquine, amodiaquine), the arylaminoalcohols (quinine, quinidine, mefloquine), and the 8-aminoquinolines (primaquine, tafenoquine). Despite structural similarities within subclasses, their mechanisms of action, target life cycle stages, toxicity profiles, and resistance patterns differ substantially.
Chloroquine and Hydroxychloroquine. Chloroquine is a 4-aminoquinoline that concentrates dramatically in the acidic digestive vacuole of the intraerythrocytic Plasmodium trophozoite, achieving vacuolar concentrations up to 1,000-fold higher than plasma. Within the digestive vacuole, the parasite catabolizes hemoglobin to amino acids; this process generates free heme (ferriprotoporphyrin IX), which is toxic to the parasite in its free form. The parasite normally detoxifies free heme by polymerizing it into insoluble hemozoin (malaria pigment). Chloroquine interferes with this polymerization by binding to free heme and forming a chloroquine-heme complex that inhibits the heme polymerase enzyme. Accumulation of toxic free heme and chloroquine-heme complexes within the digestive vacuole disrupts membrane integrity and kills the parasite. Chloroquine is active against erythrocytic stages of all four human Plasmodium species but has no activity against hepatic stages or hypnozoites.5
Hydroxychloroquine shares the same mechanism as chloroquine with a hydroxyl group substitution on the terminal nitrogen that reduces its entry into ocular tissues and slightly modifies its tissue distribution. For malaria specifically, chloroquine and hydroxychloroquine are considered interchangeable in mechanism and spectrum; hydroxychloroquine is more commonly used in its non-malarial applications (rheumatoid arthritis, systemic lupus erythematosus, COVID-19 research) than for malaria treatment. Chloroquine pharmacokinetics are characterized by an enormous volume of distribution (200 to 800 L/kg) due to extensive tissue binding, a terminal elimination half-life of 1 to 2 months, and renal excretion of the unchanged drug and its active metabolite desethylchloroquine. This long half-life means that therapeutic concentrations persist for weeks after the last dose, providing residual prophylactic activity but also prolonging toxicity if it develops.8
Quinine and Quinidine. Quinine is the prototype antimalarial quinoline, the active alkaloid of Cinchona bark, used clinically for over 400 years. Like chloroquine, quinine concentrates in the digestive vacuole and interferes with heme polymerization, but it also intercalates into parasite deoxyribonucleic acid (DNA) and disrupts multiple intracellular processes. Quinine retains activity against chloroquine-resistant P. falciparum strains, making it a critical second-line and salvage agent. Its narrow therapeutic index, multiple drug interactions, and requirement for combination therapy (always given with doxycycline or clindamycin for 7 days to reduce resistance selection) limit its outpatient use. Quinidine, the dextrorotatory stereoisomer of quinine, is slightly more potent as an antimalarial and significantly more potent as a cardiac antiarrhythmic (class IA); it was the preferred IV agent for severe malaria in the United States before IV artesunate became available.7
Cinchonism, the characteristic toxicity syndrome of quinine and quinidine, consists of tinnitus, high-frequency hearing loss, headache, nausea, dysphoria, and visual disturbances. It occurs at therapeutic or mildly supratherapeutic concentrations and is not dose-limiting in the short courses used for malaria treatment. More serious quinine toxicities include hypoglycemia (stimulation of pancreatic insulin secretion, exacerbated by falciparum malaria itself which depletes glucose), QTc prolongation (pronounced with quinidine, clinically significant with quinine at high doses), and, rarely, quinine-induced immune thrombocytopenic purpura or hemolytic uremic syndrome. Blackwater fever (massive intravascular hemolysis and hemoglobinuria in the context of P. falciparum infection) has historically been associated with quinine use in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients, though the pathogenesis involves the infection itself as well as the drug.78
Mefloquine. Mefloquine is an arylaminoalcohol structurally related to quinine that acts on erythrocytic stages of Plasmodium by interfering with heme polymerization and disrupting membrane function. Its exceptionally long half-life (2 to 3 weeks) makes it suitable for once-weekly prophylaxis. Mefloquine retains activity against most chloroquine-resistant P. falciparum strains, though mefloquine-resistant strains are established in Southeast Asia (particularly the Thailand-Cambodia border region), where artesunate-mefloquine combinations have faced treatment failures. The most important limitation of mefloquine is a 25 to 30 percent incidence of neuropsychiatric adverse effects at prophylactic doses, including vivid or disturbing dreams, sleep disturbances, anxiety, dizziness, and in a smaller proportion of recipients, frank psychosis, seizures, or prolonged neuropsychiatric sequelae. The FDA added a black box warning for mefloquine neuropsychiatric effects in 2013; it is contraindicated in patients with a history of psychiatric disorders, seizures, or depression, and should be started 2 to 3 weeks before travel (rather than the conventional 1 week) to allow assessment of tolerability before departure.9
Primaquine. Primaquine is the prototype 8-aminoquinoline and is unique among antimalarials in its activity against hypnozoites in the liver (the source of relapse in P. vivax and P. ovale infections), against hepatic schizonts (causal prophylaxis), and against mature P. falciparum gametocytes (transmission blocking). Its mechanism is not fully characterized but involves generation of reactive oxygen species (ROS) within parasite mitochondria, disruption of the mitochondrial electron transport chain, and oxidative damage to parasite DNA and membranes. The critical pharmacogenomic consideration with primaquine is G6PD deficiency: primaquine generates oxidative metabolites that overwhelm the glutathione-dependent antioxidant defense in G6PD-deficient erythrocytes, causing dose-dependent hemolytic anemia. The severity of hemolysis is proportional to the degree of G6PD deficiency (WHO classification A- variant common in African populations produces mild-moderate hemolysis; Mediterranean and Asian variants cause severe, potentially life-threatening hemolysis at standard doses). G6PD quantitative testing (not qualitative screening) is mandatory before prescribing primaquine for radical cure of P. vivax or P. ovale.14
| Agent | Class | Target Stage | Key Toxicity | G6PD Required |
|---|---|---|---|---|
| Chloroquine | 4-Aminoquinoline | Blood schizonts | Retinopathy (long-term), QTc | No |
| Hydroxychloroquine | 4-Aminoquinoline | Blood schizonts | Retinopathy (less than CQ) | No |
| Quinine | Arylaminoalcohol | Blood schizonts | Cinchonism, hypoglycemia, QTc | Relative |
| Quinidine | Arylaminoalcohol | Blood schizonts | QTc prolongation, cinchonism | Relative |
| Mefloquine | Arylaminoalcohol | Blood schizonts | Neuropsychiatric (25-30%) | No |
| Primaquine | 8-Aminoquinoline | Hypnozoites, gametocytes, hepatic schizonts | Hemolytic anemia (G6PD deficiency) | Yes—mandatory |
Chloroquine resistance is now widespread in sub-Saharan Africa, Southeast Asia, and most malaria-endemic regions; never use chloroquine monotherapy for P. falciparum from these areas. Quinine must always be combined with doxycycline or clindamycin for 7 days—monotherapy selects resistance. Mefloquine: start 2–3 weeks before travel; contraindicated in psychiatric disease, seizures, and cardiac conduction abnormalities. Primaquine and tafenoquine: G6PD quantitative test mandatory before prescribing—qualitative testing insufficient for tafenoquine due to its greater hemolytic potential.
Artemisinin and its derivatives represent the most important advance in antimalarial pharmacology in the modern era. First isolated from Artemisia annua (sweet wormwood) by Youyou Tu and colleagues in China in the 1970s, artemisinins act rapidly against all erythrocytic stages of Plasmodium, including the ring forms that are most difficult to target, and reduce parasite biomass by up to 10,000-fold per 48-hour cycle, a parasite-killing rate unmatched by any other antimalarial class. Because of their short half-lives, artemisinins are always combined with a longer-acting partner drug in an artemisinin-based combination therapy (ACT) to prevent recrudescence and slow the emergence of resistance.
Mechanism of Action. Artemisinins contain a 1,2,4-trioxane ring with an endoperoxide bridge that is essential for antimalarial activity. This endoperoxide bridge is activated by ferrous iron (Fe2+) within the parasite digestive vacuole, where heme digestion generates abundant free ferrous iron. Iron-mediated cleavage of the endoperoxide bridge produces highly reactive carbon-centered free radicals that alkylate and damage a broad range of parasite proteins and lipids, including the sarcoplasmic-endoplasmic reticulum calcium ATPase (SERCA) ortholog PfATP6, heme itself, and multiple membrane components. The multi-target mechanism is believed to contribute to the lower rate of resistance development compared with single-target drugs. Artemisinins also depolarize the parasite plasma membrane and impair mitochondrial function, adding to their broad cytotoxic effect on all intraerythrocytic parasite stages.7
Pharmacokinetics and the Rationale for Combination. Artesunate, the most widely used intravenous and oral artemisinin derivative, is a water-soluble hemisuccinate ester that is rapidly hydrolyzed in plasma to the active metabolite dihydroartemisinin (DHA). DHA is pharmacologically active, achieves peak plasma concentrations within 1 to 2 hours after oral artesunate, and is cleared with a half-life of only 1 to 2 hours. This extremely short half-life means that artesunate monotherapy requires dosing every 8 to 12 hours and, if discontinued before the full 7-day course, leaves a sub-therapeutic drug exposure window during which surviving parasites can develop resistance. Artemether, the fat-soluble methyl ether artemisinin derivative used in artemether-lumefantrine (Coartem), is absorbed more slowly, metabolized by cytochrome P450 3A4 (CYP3A4) to DHA, and has a slightly longer half-life than artesunate, but still too short for monotherapy. The pairing with lumefantrine, which has a half-life of 3 to 6 days, ensures that parasites surviving the artemisinin rapid-kill phase are eliminated by sustained lumefantrine exposure, completing the treatment course.3
WHO-Recommended ACT Regimens for Uncomplicated P. falciparum Malaria. The World Health Organization (WHO) recommends five ACTs as first-line treatment for uncomplicated P. falciparum malaria: (1) artemether-lumefantrine, the most widely used globally; (2) artesunate-amodiaquine; (3) artesunate-mefloquine, preferred in Southeast Asia; (4) artesunate-sulfadoxine-pyrimethamine (SP), used where SP resistance is low; and (5) dihydroartemisinin-piperaquine. The choice among ACTs is guided by regional resistance patterns, drug availability, cost, and patient factors. Artemether-lumefantrine is the most extensively studied, is well-tolerated, and has demonstrated greater than 95 percent cure rates in most settings. Lumefantrine absorption is significantly enhanced by co-administration with fat-containing food; patients and caregivers must be counseled that taking artemether-lumefantrine with a fatty meal is not optional but required for adequate bioavailability.3
Intravenous Artesunate for Severe Malaria. Severe P. falciparum malaria, defined by WHO criteria including impaired consciousness, respiratory distress, severe anemia, hyperparasitemia above 5 percent, acute kidney injury, or circulatory collapse, is a medical emergency with mortality rates of 15 to 25 percent even with treatment. IV artesunate is the treatment of choice for severe malaria globally, having demonstrated superiority over IV quinine in two large randomized controlled trials (AQUAMAT [African Quinine Artesunate Malaria Trial] in Africa, SEAQUAMAT [Southeast Asian Quinine Artesunate Malaria Trial] in Asia) with approximately 35 percent relative reduction in mortality. IV artesunate is administered as 2.4 mg/kg at 0, 12, and 24 hours, then once daily until oral therapy is possible, typically for a minimum of 24 hours before transition to a full oral ACT course. Post-artesunate delayed hemolysis (PADH) is an important adverse effect: in patients with high initial parasitemia, destruction of once-parasitized erythrocytes (which survive the artemisinin assault and are later cleared by the spleen) can produce hemolysis 2 to 3 weeks after completing treatment; hemoglobin monitoring should continue for 4 weeks after IV artesunate in high-parasitemia cases.11
Safety Profile of Artemisinins. Artemisinins are among the best-tolerated antimalarials. The most clinically significant concern is cardiac: artemisinins can prolong the QTc interval, and combination partners such as lumefantrine, mefloquine, and amodiaquine add further QTc prolongation risk. In patients with pre-existing QTc prolongation, cardiac disease, or concurrent QT interval (QT)-prolonging medications, this combination risk warrants electrocardiogram (ECG) monitoring or selection of an alternative ACT. Artemisinins are embryotoxic in animal studies; first-trimester pregnancy is a relative contraindication, and IV quinine plus clindamycin remains the preferred treatment for severe malaria in the first trimester. From the second trimester onward, ACTs are considered appropriate and are preferred over alternatives given the far greater mortality risk of undertreated severe malaria. Neurotoxicity has been demonstrated in animal models at doses exceeding clinical exposure; no confirmed neurotoxicity has been established in humans at therapeutic doses, but the concern has guided dose ceiling recommendations.3
Artemether-lumefantrine must be taken with fatty food—bioavailability of lumefantrine drops 10-fold in fasted state. IV artesunate for severe malaria: 2.4 mg/kg at 0, 12, 24 hours then daily; superior to IV quinine (35% mortality reduction). Monitor hemoglobin for 4 weeks after IV artesunate in high-parasitemia cases (post-artesunate delayed hemolysis). First-trimester pregnancy: use IV quinine + clindamycin for severe malaria; ACTs acceptable from second trimester. Southeast Asia P. falciparum: partial artemisinin resistance (kelch13 mutations) documented; extend treatment to 5–7 days or use alternative ACT partner.
Antimalarial prophylaxis is one of the most individualized decisions in travel medicine, requiring integration of destination-specific resistance patterns, travel duration, patient medical history, tolerability, and cost. The four primary prophylactic agents in current use (chloroquine, mefloquine, atovaquone-proguanil, and doxycycline) differ in mechanism (causal versus suppressive), required dosing frequency, side-effect profiles, drug interactions, and contraindications. No single agent is optimal for all travelers, and the prescriber must actively match drug to patient rather than defaulting to a single regimen.
Chloroquine. Chloroquine remains the recommended prophylactic agent for malaria-endemic areas where P. falciparum remains chloroquine-sensitive, essentially limited to Central America west of the Panama Canal, Haiti, the Dominican Republic, and parts of the Middle East. For all other malaria-endemic destinations, chloroquine-resistant P. falciparum is present, and chloroquine alone is inadequate. Chloroquine prophylaxis is given as 500 mg salt (300 mg base) once weekly, starting 1 to 2 weeks before travel, continuing throughout, and for 4 weeks after leaving the endemic area. Its once-weekly dosing, long safety record in pregnancy, and low cost make it preferable when destination resistance patterns permit. The major limitation beyond resistance is retinal toxicity with long-term continuous use (above 5 years at prophylactic doses); this is rarely an issue for travel prophylaxis but is highly relevant for patients on long-term chloroquine or hydroxychloroquine for rheumatologic indications.612
Atovaquone-Proguanil. Atovaquone-proguanil (Malarone) is a fixed-dose combination that acts as a causal prophylactic, killing hepatic schizonts before blood-stage infection is established. Atovaquone inhibits the mitochondrial electron transport chain of Plasmodium by binding cytochrome bc1 (complex III) and disrupting ubiquinol oxidation, collapsing mitochondrial membrane potential; proguanil acts synergistically through its active metabolite cycloguanil, which inhibits dihydrofolate reductase (DHFR), and also independently potentiates atovaquone’s mitochondrial effect through a DHFR-independent mechanism. Because atovaquone-proguanil kills hepatic-stage parasites, it can be stopped 7 days after leaving the endemic area rather than the 4 weeks required for suppressive prophylactics, a significant advantage for travelers. It is given once daily, starting 1 to 2 days before travel. Tolerability is generally good; gastrointestinal adverse effects (nausea, abdominal discomfort) occur in approximately 10 to 15 percent of users and are reduced by taking the tablet with food or a milky drink. Atovaquone-proguanil is contraindicated in severe renal impairment (creatinine clearance below 30 mL/min) due to the renal excretion of proguanil metabolites, and is not recommended in pregnancy (safety data insufficient) or while breastfeeding infants under 5 kg.12
Doxycycline. Doxycycline acts as a causal prophylactic by inhibiting Plasmodium protein synthesis through binding to the 30S ribosomal subunit of the apicoplast, a non-photosynthetic plastid organelle in Plasmodium that retains a prokaryotic-like ribosome and is essential for fatty acid and isoprenoid biosynthesis. Doxycycline is given 100 mg once daily, starting 1 to 2 days before travel and continuing for 4 weeks after leaving the endemic area (it has both causal and suppressive activity). It is active against chloroquine-resistant and mefloquine-resistant P. falciparum and is one of the preferred agents for travel to Southeast Asia. Clinical considerations include: photosensitivity (patients must use high-SPF sun protection, a particular concern in tropical destinations), esophageal ulceration (must be taken with at least 200 mL water and not immediately before lying down), vaginal candidiasis in women (approximately 30 percent with prolonged use), and gastrointestinal (GI) intolerance (reduced by taking with food). Doxycycline is absolutely contraindicated in pregnancy and in children under 8 years of age due to effects on bone and tooth development. It has cytochrome P450 3A4 (CYP3A4)-independent pharmacokinetics but chelates divalent cations, requiring a 2-hour separation from calcium, iron, and antacid supplements.12
Primaquine as Prophylaxis. Primaquine can be used as a causal prophylactic in adults at 30 mg base daily (versus 15 mg base daily for radical cure), starting 1 to 2 days before travel and stopping 7 days after return (causal activity allows early discontinuation as with atovaquone-proguanil). It provides broad spectrum prophylaxis including against P. vivax hypnozoites, making it particularly useful for travelers to areas with high P. vivax burden. Its use requires glucose-6-phosphate dehydrogenase (G6PD) testing, limiting application in populations where testing is unavailable. GI adverse effects are common at the higher prophylactic dose; taking with food reduces but does not eliminate them.4
| Agent | Mechanism Type | Dosing | Start Before Travel | Stop After Return | Key Contraindications |
|---|---|---|---|---|---|
| Chloroquine | Suppressive | 500 mg weekly | 1–2 weeks | 4 weeks | Resistant areas (most of world) |
| Mefloquine | Suppressive | 250 mg weekly | 2–3 weeks | 4 weeks | Psychiatric Hx, seizures, cardiac conduction Dz |
| Atovaquone-Proguanil | Causal | 250/100 mg daily | 1–2 days | 7 days | CrCl <30 mL/min, pregnancy, infant <5 kg |
| Doxycycline | Causal/Suppressive | 100 mg daily | 1–2 days | 4 weeks | Pregnancy, age <8 years |
| Primaquine | Causal | 30 mg base daily | 1–2 days | 7 days | G6PD deficiency, pregnancy |
Central America (CQ-sensitive areas), Haiti: chloroquine acceptable. Sub-Saharan Africa, South Asia: atovaquone-proguanil or doxycycline preferred; mefloquine acceptable if no psychiatric Hx. Southeast Asia (Thailand-Cambodia border, Myanmar): doxycycline or atovaquone-proguanil; mefloquine resistance limits use. P. vivax-dominant areas (Papua New Guinea, Solomon Islands): add primaquine or tafenoquine terminal prophylaxis after G6PD testing. Pregnancy: chloroquine for CQ-sensitive areas; mefloquine from second trimester for resistant areas; doxycycline and atovaquone-proguanil contraindicated.
The antimalarial drug class carries a distinctive set of toxicities that are mechanistically linked to their pharmacological targets and physicochemical properties. Retinopathy from chloroquine and hydroxychloroquine, corrected QT (QTc) prolongation from quinoline class agents, hemolytic anemia from 8-aminoquinolines in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients, and neuropsychiatric effects from mefloquine represent the four most clinically significant toxicity domains, each requiring specific monitoring strategies and clear prescribing thresholds.
Retinopathy. Chloroquine and hydroxychloroquine accumulate preferentially in melanin-containing tissues, including the retinal pigment epithelium (RPE). Chronic accumulation in the RPE disrupts lysosomal function within RPE cells and causes progressive, dose-dependent, and unfortunately largely irreversible damage to photoreceptors in a characteristic bull’s-eye maculopathy pattern. Chloroquine is approximately 2- to 3-fold more retinotoxic than hydroxychloroquine at equivalent doses, reflecting higher ocular accumulation. For travel prophylaxis (short-term use), retinal toxicity is not a practical concern. For long-term use in rheumatologic conditions, the American Academy of Ophthalmology (AAO) recommends baseline ophthalmologic evaluation at the start of therapy, followed by annual monitoring after 5 years of use (or earlier in high-risk patients: pre-existing retinal disease, renal impairment, tamoxifen co-use, or cumulative dose above 1,000 g hydroxychloroquine). The AAO safe dosing threshold is 5 mg/kg actual body weight per day for hydroxychloroquine and 2.3 mg/kg/day for chloroquine; doses above these thresholds carry substantially higher retinopathy risk. Screening modalities include automated visual fields (10-2 program), spectral-domain optical coherence tomography (SD-OCT), and multifocal electroretinography (mfERG).6
QTc Prolongation. Multiple antimalarials prolong cardiac repolarization by blocking the cardiac rapid delayed rectifier potassium channel (IKr), encoded by the hERG gene. Quinidine is the most potent cardiac channel blocker in this class (it is used therapeutically as a class IA antiarrhythmic) and carries the highest QTc (corrected QT interval) prolongation risk; IV quinidine for severe malaria requires continuous cardiac monitoring. Quinine prolongs QTc at therapeutic doses; the risk is amplified by hypokalemia and hypomagnesemia, which are common in severe falciparum malaria, and by co-administration with other QT-prolonging agents. Mefloquine produces modest QTc prolongation; it is contraindicated with halofantrine (a no-longer-recommended antimalarial) and should be used with caution with other QT-prolonging agents. Lumefantrine in artemether-lumefantrine and piperaquine in dihydroartemisinin-piperaquine also prolong QTc; piperaquine carries a stronger QTc signal than lumefantrine. The clinical threshold for discontinuation or substitution is a QTc above 500 ms or an increase of more than 60 ms from baseline; patients with congenital long QT syndrome, structural heart disease, or electrolyte abnormalities should have electrocardiogram (ECG) monitoring when QT-prolonging antimalarials are prescribed.78
Hemolytic Anemia and G6PD Deficiency. Glucose-6-phosphate dehydrogenase deficiency is the most common human enzyme deficiency, affecting approximately 400 million people globally and showing highest prevalence in malaria-endemic regions of Africa, the Mediterranean, Middle East, and Southeast Asia, a distribution consistent with heterozygote advantage against P. falciparum. G6PD catalyzes the rate-limiting step of the pentose phosphate pathway in erythrocytes, generating nicotinamide adenine dinucleotide phosphate (NADPH), which is essential for maintaining glutathione in its reduced (antioxidant) form. G6PD-deficient erythrocytes cannot neutralize oxidative stress; when challenged by oxidative antimalarial metabolites (primaquine, tafenoquine, dapsone), hemoglobin denatures to form Heinz bodies and erythrocytes are destroyed by intravascular and extravascular hemolysis. The degree of hemolysis is determined by both the severity of G6PD deficiency (WHO Class I–V) and the dose and duration of the oxidant drug. Primaquine at 15 mg base daily for 14 days causes clinically significant hemolysis in Class II and III G6PD-deficient patients; tafenoquine as a single 300 mg dose causes more severe hemolysis at lower G6PD activity thresholds. Monitoring hemoglobin at day 3 and day 8 of primaquine therapy allows early detection of hemolysis in patients with intermediate G6PD activity who clear G6PD testing thresholds.14
Neuropsychiatric Effects of Mefloquine. Mefloquine crosses the blood-brain barrier and accumulates in the central nervous system. Its neuropsychiatric toxicity includes a spectrum from mild (vivid dreams, sleep disturbance, dizziness, anxiety, difficulty concentrating) to severe (acute psychosis, depression, panic attacks, seizures, suicidal ideation, prolonged neurological sequelae lasting months to years after discontinuation). The incidence of neuropsychiatric side effects sufficient to cause discontinuation is approximately 1 in 10,000 at prophylactic doses in military populations, but mild neuropsychiatric symptoms occur in 25 to 30 percent of prophylaxis recipients. The FDA black box warning (2013) specifies that neuropsychiatric adverse events may persist after mefloquine is discontinued; patients must be counseled before starting therapy and should stop immediately and seek evaluation if psychiatric symptoms develop. The mechanism of neuropsychiatric toxicity is not fully established but may involve adenosine receptor antagonism and inhibition of multi-drug resistance-associated proteins (MRP) at the blood-brain barrier that normally export mefloquine from central nervous system (CNS) tissue. Mefloquine is absolutely contraindicated with a personal history of active or recent depression, generalized anxiety disorder, psychosis, or schizophrenia; a history of seizures; or use of drugs that lower the seizure threshold.9
Chloroquine/hydroxychloroquine long-term: baseline eye exam; annual monitoring after year 5; safe dose ceiling hydroxychloroquine 5 mg/kg/day. QTc: check ECG at baseline for quinine IV, quinidine IV, or piperaquine-containing ACT; correct hypokalemia and hypomagnesemia; threshold for intervention QTc above 500 ms. G6PD: quantitative test before any 8-aminoquinoline; check hemoglobin at day 3 and day 8 of primaquine. Mefloquine: pre-travel psychiatric screening; start 2–3 weeks before departure to detect intolerance before remote destination; stop immediately if psychiatric symptoms develop.
Antimalarial drug resistance is a major global health threat that has progressively eroded the clinical utility of successive drug classes. Chloroquine resistance became widespread in the 1960s and effectively eliminated chloroquine as a treatment option for P. falciparum in most of the world. Sulfadoxine-pyrimethamine (SP) resistance followed within decades. Resistance to artemisinins, the cornerstone of current therapy, is now confirmed in Southeast Asia and has been detected in Africa, raising urgent concerns about the durability of the current artemisinin-based combination therapy (ACT) era.
Chloroquine Resistance. Chloroquine resistance in P. falciparum is mediated primarily by mutations in the pfcrt gene (encoding the Plasmodium falciparum chloroquine resistance transporter), with the lysine-to-threonine substitution at position 76 (K76T) mutation being the key determinant. PfCRT normally resides in the digestive vacuole membrane; the K76T mutant transporter exports chloroquine from the digestive vacuole, reducing drug accumulation and preventing lethal heme complex formation. Secondary mutations in pfmdr1 (the P-glycoprotein homolog 1 gene) modulate the degree of resistance. Chloroquine-resistant P. falciparum emerged independently in Southeast Asia, South America, and East Africa in the 1950s to 1960s, and resistant strains now predominate in virtually all P. falciparum-endemic regions outside Central America and Haiti. In P. vivax, chloroquine resistance is mediated by different mechanisms (including pvcrt and pvmdr1 mutations) and was first confirmed in Papua New Guinea; significant P. vivax chloroquine resistance is now documented in Southeast Asia and the Pacific.12
Sulfadoxine-Pyrimethamine Resistance. Sulfadoxine-pyrimethamine (SP) inhibits two sequential steps in folate biosynthesis: pyrimethamine inhibits DHFR (dihydrofolate reductase) and sulfadoxine inhibits DHPS (dihydropteroate synthase). SP resistance accumulates sequentially through single-nucleotide polymorphisms (SNPs) in pfdhfr (N51I, C59R, S108N, I164L) and pfdhps (A437G, K540E, A581G), with each additional mutation incrementally reducing susceptibility. The combination of dhfr triple mutation (N51I/C59R/S108N) with dhps double mutation (A437G/K540E) produces the “quintuple mutant” associated with clinical SP treatment failure. Quintuple mutants now predominate across sub-Saharan Africa, rendering SP unsuitable as a standalone treatment. SP retains its role in intermittent preventive treatment in pregnancy (IPTp) in areas where parasite tolerance has not reached the highest resistance levels, and in seasonal malaria chemoprevention (SMC) in the Sahel region using SP plus amodiaquine.12
Artemisinin Partial Resistance. Partial resistance to artemisinins, first confirmed on the Thailand-Cambodia border in 2008 and now documented across the Greater Mekong Subregion and in East Africa, is mediated primarily by mutations in the pfkelch13 gene (also called PfK13). The Kelch13 propeller domain mutations (principally cysteine-to-tyrosine at position 580 [C580Y], R539T, Y493H, and I543T) cause upregulation of the unfolded protein response and reduce the rate of hemoglobin digestion, decreasing the free ferrous iron pool that activates the artemisinin endoperoxide bridge. The result is slowed parasite killing without complete resistance: artemisinin-resistant parasites survive the ring-stage drug exposure in a state of reduced metabolic activity, emerge when drug levels fall, and show “delayed clearance” (half-life of parasite clearance above 5 hours versus the normal 2 to 3 hours). In the absence of resistant ACT partner drugs, artemisinin partial resistance alone does not cause clinical treatment failure in most cases. The major threat occurs when partner drug resistance co-evolves: piperaquine resistance in Cambodia (mediated by plasmepsin 2-3 amplification) combined with PfK13 (Kelch13) mutations produced high-level ACT treatment failure rates in Southeast Asia, driving a shift to artesunate-mefloquine as first-line therapy in the region.1013
Clinical Implications of Resistance Monitoring. WHO maintains a real-time resistance map (WorldWide Antimalarial Resistance Network, WWARN) that informs national treatment guidelines. For the prescribing clinician, the practical implications are: (1) never use chloroquine monotherapy for treatment of P. falciparum unless origin is definitively a chloroquine-sensitive area and susceptibility is confirmed; (2) use ACTs with region-appropriate partner drugs: lumefantrine for most of Africa, mefloquine or dihydroartemisinin-piperaquine for Southeast Asia based on current local failure rates; (3) if travel history includes Southeast Asia and treatment response is inadequate at 72 hours (parasite positivity on blood smear despite ACT), suspect artemisinin partial resistance and switch to IV artesunate while extending total treatment duration; (4) treatment failure (recurrent parasitemia within 28 days) must be distinguished from reinfection by molecular genotyping when possible, as recrudescence indicates drug failure whereas reinfection indicates only continued exposure risk.313
pfcrt K76T: primary chloroquine resistance marker; present in virtually all P. falciparum from sub-Saharan Africa, Asia, South America. pfkelch13 C580Y: dominant artemisinin partial resistance mutation in Southeast Asia; now detected in Rwanda and Uganda (Africa). Delayed clearance definition: parasite clearance half-life above 5 hours on artesunate monotherapy. Partner drug resistance (piperaquine resistance via plasmepsin 2-3 amplification) combined with K13 mutations = clinical ACT failure. Treatment failure within 28 days = recrudescence until proven otherwise; send blood for PCR genotyping and switch drug class.
Life cycle: hypnozoites (P. vivax, P. ovale) require 8-aminoquinoline radical cure; blood-stage drugs do not eliminate relapse reservoir. Chloroquine: restricted to CQ-sensitive areas (Central America west of Panama Canal, Haiti, parts of Middle East). ACT first-line for all uncomplicated P. falciparum: artemether-lumefantrine with food; IV artesunate for severe malaria. Prophylaxis: atovaquone-proguanil or doxycycline for resistant areas; mefloquine only if no psychiatric contraindication; start mefloquine 2–3 weeks before departure. G6PD testing mandatory before primaquine or tafenoquine. QTc monitoring for IV quinine, quinidine, or piperaquine-containing ACTs. Kelch13 mutations + partner drug resistance = clinical treatment failure in Southeast Asia.
Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39(9):1336-1345.
doi:10.1086/424663Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002;415(6872):673-679.
doi:10.1038/415673aWorld Health Organization. Guidelines for the Treatment of Malaria. 3rd ed. Geneva: WHO; 2015. ISBN 9789241549127.
who.int/publications/i/item/9789241549127Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380(3):215-228.
doi:10.1056/NEJMoa1710775Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6(4):861-871.
doi:10.1016/s1097-2765(05)00077-8Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386-1394.
doi:10.1016/j.ophtha.2016.01.058Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):181-192.
doi:10.4269/ajtmh.2007.77.181Brunton L, Knollmann B, Hilal-Dandan R, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill; 2023. Chapter 49: Chemotherapy of Malaria.
doi:10.1036/9781264258987Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis. 2009;7(1):2-6.
doi:10.1016/j.tmaid.2008.12.004Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50-55.
doi:10.1038/nature12876Dondorp AM, Fanello CI, Hendriksen ICE, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-1657.
doi:10.1016/S0140-6736(10)61924-1Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev. 2008;21(3):466-472.
doi:10.1128/CMR.00059-07Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411-423.
doi:10.1056/NEJMoa1314981